<table>
<thead>
<tr>
<th>BNF Ref.</th>
<th>RAG Status</th>
<th>Place in therapy</th>
<th>Drug Name</th>
<th>Form &amp; Strength</th>
<th>Brand (if applicable)</th>
<th>Main Indication / Action</th>
<th>Link to SPC</th>
<th>NICE</th>
<th>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</th>
<th>Special / ACBS / SLS</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1.1</td>
<td>Amber</td>
<td></td>
<td>Chlorambucil</td>
<td>2mg tablet</td>
<td>Alkylating drugs</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1g tablets significantly more expensive than 2 x 500mg capsules</td>
</tr>
<tr>
<td>8.1.1</td>
<td>Amber</td>
<td></td>
<td>Melphalan</td>
<td>2mg tablet, 50mg injection</td>
<td>Alkylating drugs</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Amber</td>
<td></td>
<td>Hydroxycarbamide (hydroxyurea)</td>
<td>500mg capsule</td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.1</td>
<td>Amber</td>
<td></td>
<td>Azathioprine</td>
<td>25mg &amp; 50mg tablet, 50mg/5ml suspension</td>
<td>Antiproliferative immunosuppressant</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.1</td>
<td>Amber post transplant except: Red when commissioned through specialist centres for use following renal transplantation</td>
<td>Mycophenolate mofetil</td>
<td>500mg tablet</td>
<td>500mg/5ml suspension</td>
<td>Antiproliferative immunosuppressant</td>
<td>SPC</td>
<td>TA461</td>
<td>renal transplant (adults)</td>
<td></td>
<td>For prevention of transplant rejection, second line for resistant nephrotic syndrome, SLE nephritis</td>
<td></td>
</tr>
<tr>
<td>8.2.1</td>
<td>Amber except: Red when commissioned through specialist centres for use following renal transplantation</td>
<td>Ciclosporin</td>
<td>10mg, 25mg, 50mg &amp; 100mg capsule, 100mg/1ml solution</td>
<td>Neoral</td>
<td>Immunosuppressant</td>
<td>SPC</td>
<td>TA461</td>
<td>renal transplant (children)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.2</td>
<td>Amber except: Red when commissioned through specialist centres for use following renal transplantation</td>
<td>Sirolimus</td>
<td>500microgram, 1mg &amp; 2mg tablet</td>
<td>Neoral</td>
<td>Immunosuppressant</td>
<td>SPC</td>
<td>TA461</td>
<td>renal transplant (adults)</td>
<td></td>
<td>Not for initial treatment to prevent organ rejection following kidney transplant</td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
<td>Comments</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>----------------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td>------</td>
<td>---------------------------------------------------------------</td>
<td>---------------------</td>
<td>----------</td>
</tr>
<tr>
<td>8.2.2</td>
<td>Amber</td>
<td>renal transplant (adults)</td>
<td>Tacrolimus</td>
<td>500 microgram, 1mg &amp; 5mg capsule</td>
<td>Prescribe by brand: Prograf</td>
<td>Immunosuppressant</td>
<td>TA481</td>
<td></td>
<td>DPC: 14.6.11 - oral solution if patients unable to swallow tablets</td>
<td>MHRA: 5(11)Jun12</td>
<td>For prevention of transplant rejection, and second line for resistant nephrotic syndrome Modigraf granules are subject to a Commercial Medicines Agreement</td>
</tr>
<tr>
<td>8.3.1</td>
<td>Green</td>
<td>renal transplant (children)</td>
<td>Diethylstilbestrol (stilboestrol)</td>
<td>1mg &amp; 5mg tablet</td>
<td>Oestrogen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.1</td>
<td>Green</td>
<td></td>
<td>Ethinylestradiol</td>
<td>10 microgram, 50 microgram &amp; 1mg tablet</td>
<td>Oestrogen</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.2</td>
<td>Green</td>
<td>SCG Liver (Prograf)</td>
<td>Medroxyprogesterone acetate</td>
<td>100mg, 200mg &amp; 400mg tablet</td>
<td>Progestogen</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.2</td>
<td>Green</td>
<td></td>
<td>Megestrol acetate</td>
<td>160mg tablet</td>
<td>Progestogen</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.2</td>
<td>Green</td>
<td></td>
<td>Norethisterone</td>
<td>5mg tablet</td>
<td>Progestogen</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.1</td>
<td>Amber</td>
<td></td>
<td>Anastrozole</td>
<td>1mg tablet</td>
<td>Aromatase inhibitor in breast cancer</td>
<td>SPC</td>
<td>TA112 breast cancer</td>
<td>DPC: 16.1.07</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.1</td>
<td>Amber</td>
<td></td>
<td>Exemestane</td>
<td>25mg tablet</td>
<td>Aromatase inhibitor in breast cancer</td>
<td>SPC</td>
<td>TA112 breast cancer</td>
<td>DPC: 16.1.07</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.1</td>
<td>Amber</td>
<td></td>
<td>Letrozole</td>
<td>2.5mg tablet</td>
<td>Aromatase inhibitor in breast cancer</td>
<td>SPC</td>
<td>TA112 breast cancer</td>
<td>DPC: 16.1.07</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.1</td>
<td>Amber</td>
<td></td>
<td>Tamoxifen</td>
<td>10mg, 20mg &amp; 40mg tablet</td>
<td>Oestrogen antagonist in breast cancer</td>
<td>SPC</td>
<td></td>
<td></td>
<td>DPC: 14.6.11 - oral solution if patients unable to swallow tablets</td>
<td>MHRA: 4(11)Nov10</td>
<td></td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Amber</td>
<td></td>
<td>Bicalutamide</td>
<td>50mg &amp; 150mg tablet</td>
<td>Gonadoreline analogues and gonadotrophin-releasing hormone antagonists</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td>DPC: 7.6.05</td>
<td></td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Amber</td>
<td></td>
<td>Cyproterone acetate</td>
<td>50mg &amp; 100mg tablet</td>
<td>Gonadoreline analogues and gonadotrophin-releasing hormone antagonists</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
<td>Comments</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>------------------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>----------</td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Amber</td>
<td>Flutamide 250mg tablet</td>
<td>Gonadorelin analogues and gonadotrophin-releasing hormone antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Amber</td>
<td>Triptorelin 3mg, 11.25mg &amp; 22.5mg injection</td>
<td>Decapeptyl SR</td>
<td>Gonadorelin analogues and gonadotrophin-releasing hormone antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Amber</td>
<td>Triptorelin 3.75mg injection</td>
<td>Gonapretyl Depot</td>
<td>Gonadorelin analogues and gonadotrophin-releasing hormone antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Amber</td>
<td>Goserelin 3.6mg implant</td>
<td>Gonadorelin analogues and gonadotrophin-releasing hormone antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Amber</td>
<td>Leuprolelin 3.75mg injection</td>
<td>Prostap SR</td>
<td>Gonadorelin analogues and gonadotrophin-releasing hormone antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Amber</td>
<td>Degarelix 80mg &amp; 120mg injection</td>
<td>Firmagon</td>
<td>Gonadorelin analogues and gonadotrophin-releasing hormone antagonists</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.3</td>
<td>Amber / Red</td>
<td>Octreotide 50microgram/1ml, 100microgram/1ml</td>
<td>Somatostatin analogue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.3</td>
<td>Amber / Red</td>
<td>Lanreotide 60mg, 90mg &amp; 120mg injection</td>
<td>Somatuline Autoject</td>
<td>Somatostatin analogue</td>
<td>For self-administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>------------------</td>
<td>------------</td>
<td>----------------</td>
<td>----------------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>------</td>
<td>----------------------------------------------------------------</td>
<td>----------------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8.3.4.3 1st choice in acromegaly</td>
<td>Octreotide</td>
<td>10mg, 20mg &amp; 30mg depot injection</td>
<td>Sandostatin Lar</td>
<td>Somatostatin analogue</td>
<td>DPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1</td>
<td>Red</td>
<td>Calcium folinate</td>
<td>tablet injection</td>
<td>Folinic acid rescue</td>
<td>SPC</td>
<td>CG131 colorectal cancer</td>
<td>TA100 colon cancer</td>
<td>TA176 colorectal cancer</td>
<td></td>
<td>For urothelial toxicity</td>
<td></td>
</tr>
<tr>
<td>8.1</td>
<td>Red</td>
<td>Mesna</td>
<td>tablet injection</td>
<td>Cytotoxic-induced side effects</td>
<td>SPC</td>
<td>TA206 non-Hodgkin lymphoma terminated</td>
<td>DPC 12.4.11 14.12.10</td>
<td>TA216 CLL</td>
<td>TA437 CLL, terminated appraisal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.1</td>
<td>Red</td>
<td>Bendamustine</td>
<td>25mg &amp; 100mg injection</td>
<td>Alkylating drugs</td>
<td>SPC</td>
<td>TA206 non-Hodgkin lymphoma terminated</td>
<td>DPC 12.4.11 14.12.10</td>
<td>TA216 CLL</td>
<td>TA437 CLL, terminated appraisal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.1</td>
<td>Red</td>
<td>Busulfan</td>
<td>tablet injection</td>
<td>Alkylating drugs</td>
<td>SPC</td>
<td>TA206 non-Hodgkin lymphoma terminated</td>
<td>DPC 12.4.11 14.12.10</td>
<td>TA216 CLL</td>
<td>TA437 CLL, terminated appraisal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Secondary Care Use Only:

NB: All cancer treatments are commissioned by NHS England
<table>
<thead>
<tr>
<th>BNF Ref.</th>
<th>RAG Status</th>
<th>Place in therapy</th>
<th>Drug Name</th>
<th>Form &amp; Strength</th>
<th>Brand (if applicable)</th>
<th>Main Indication / Action</th>
<th>Link to SPC</th>
<th>NICE</th>
<th>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</th>
<th>Special / ACBS / SLS</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1.1</td>
<td>Red</td>
<td></td>
<td>Carmustine</td>
<td>injection</td>
<td>Alkylating drugs</td>
<td>DPC</td>
<td>TA121</td>
<td></td>
<td>glioma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7.7mg implant</td>
<td></td>
<td></td>
<td>TA149</td>
<td></td>
<td>glioblastoma, terminated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.1</td>
<td>Red</td>
<td></td>
<td>Cyclophosphamide</td>
<td>tablet</td>
<td>Alkylating drugs</td>
<td>DPC</td>
<td>TA109</td>
<td></td>
<td>breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>injection</td>
<td></td>
<td></td>
<td>TA174</td>
<td></td>
<td>CLL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA193</td>
<td></td>
<td>CLL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.1</td>
<td>Red</td>
<td></td>
<td>Ifosfamide</td>
<td>injection</td>
<td>Alkylating drugs</td>
<td>DPC</td>
<td>TA222</td>
<td></td>
<td>non-Hodgkins lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.1</td>
<td>Red</td>
<td></td>
<td>Lomustine</td>
<td>capsule</td>
<td>Alkylating drugs</td>
<td>DPC</td>
<td>TA306</td>
<td></td>
<td>non-Hodgkins lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.2</td>
<td>Red</td>
<td></td>
<td>Bleomycin</td>
<td>injection</td>
<td>Anthracyclines</td>
<td>DPC</td>
<td>TA369</td>
<td></td>
<td>pegylated liposomal in ovarian cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.2</td>
<td>Red</td>
<td></td>
<td>Daunorubicin</td>
<td>injection</td>
<td>Anthracyclines</td>
<td>DPC</td>
<td>TA389</td>
<td></td>
<td>pegylated liposomal in ovarian cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.2</td>
<td>Red</td>
<td></td>
<td>Epirubicin</td>
<td>injection</td>
<td>Anthracyclines</td>
<td>DPC</td>
<td>TA406</td>
<td></td>
<td>pegylated liposomal in ovarian cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.2</td>
<td>Red</td>
<td></td>
<td>Idarubicin</td>
<td>capsule / injection</td>
<td>Anthracyclines</td>
<td>DPC</td>
<td>TA445</td>
<td></td>
<td>pegylated liposomal in ovarian cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.2</td>
<td>Red</td>
<td></td>
<td>Mitomycin</td>
<td>injection</td>
<td>Anthracyclines</td>
<td>DPC</td>
<td>TA468</td>
<td></td>
<td>pegylated liposomal in ovarian cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.2</td>
<td>Red</td>
<td></td>
<td>Mitoxantrone</td>
<td>injection</td>
<td>Anthracyclines</td>
<td>DPC</td>
<td>TA506</td>
<td></td>
<td>non-Hodgkins lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.2</td>
<td>Red</td>
<td></td>
<td>Pixantrone</td>
<td>injection</td>
<td>Anthracyclines</td>
<td>DPC</td>
<td>TA577</td>
<td></td>
<td>non-Hodgkins lymphoma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BNF Ref.</th>
<th>RAG Status</th>
<th>Place in therapy</th>
<th>Drug Name</th>
<th>Form &amp; Strength</th>
<th>Brand (if applicable)</th>
<th>Main Indication / Action</th>
<th>Link to SPC</th>
<th>NICE</th>
<th>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</th>
<th>Special / ACBS / SLS</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Azacitidine</td>
<td>100mg injection</td>
<td>Antimetabolites</td>
<td>TA218 myelodysplastic</td>
<td>DPC</td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Cepetibine</td>
<td>250mg &amp; 500mg tablet</td>
<td>Antimetabolites</td>
<td>TA65 colorectal cancer</td>
<td>DPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Cladribine</td>
<td>Injection</td>
<td>selective immunosuppresant</td>
<td>TA493 - relapsing-remitting MS</td>
<td>DPC</td>
<td></td>
<td>MHRA:11(15)Dec17 Dec 2017: Specialised commissioning circular for MS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Cytarabine</td>
<td>Injection</td>
<td>Antimetabolites</td>
<td>TA26 CLL</td>
<td>DPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Fludarabine</td>
<td>tablet injection</td>
<td>Antimetabolites</td>
<td>TA115 lymphocytic leukaemia, no recommendation</td>
<td>DPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Fluorouracil</td>
<td>Injection</td>
<td>Antimetabolites</td>
<td>CG131 colorectal cancer</td>
<td>DPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>----------------</td>
<td>-----------------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td>------</td>
<td>---------------------------------------------------------------</td>
<td>----------------------</td>
<td>----------</td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Therapy</td>
<td>Gemcitabine</td>
<td>injection</td>
<td></td>
<td>Antimetabolites</td>
<td>SPC</td>
<td></td>
<td>TA235 pancreatic cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA116 breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Therapy</td>
<td>Mercaptopurine</td>
<td>tablet</td>
<td></td>
<td>Antimetabolites</td>
<td>SPC</td>
<td></td>
<td>TA285 ovarian cancer, not recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Therapy</td>
<td>Methotrexate</td>
<td>injection</td>
<td></td>
<td>Antimetabolites</td>
<td>SPC</td>
<td></td>
<td>TA285 ovarian cancer, not recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Therapy</td>
<td>Pemetrexed</td>
<td>100mg &amp; 500mg injection</td>
<td></td>
<td>Antimetabolites</td>
<td>SPC</td>
<td></td>
<td>TA324 non small cell lung cancer, not recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA335 mesothelioma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Therapy</td>
<td>Temozolomide</td>
<td>injection</td>
<td></td>
<td>Antimetabolites</td>
<td>SPC</td>
<td></td>
<td>TA381 non small cell lung cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA390 non small cell lung cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Red</td>
<td>Therapy</td>
<td>Trifluoridine &amp; tipiracil</td>
<td>15mg/6.14 mg &amp; 20mg/8.19mg tablet</td>
<td>Lonsurf</td>
<td>Cytotoxic</td>
<td>SPC</td>
<td></td>
<td>TA406 metastatic colorectal cancer</td>
<td></td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td>8.1.4</td>
<td>Red</td>
<td>Therapy</td>
<td>Etoposide</td>
<td>capsule &amp; injection</td>
<td>Etoposide</td>
<td></td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.4</td>
<td>Red</td>
<td>Therapy</td>
<td>Vinblastine</td>
<td>injection</td>
<td></td>
<td>Vinca alkaloid</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.4</td>
<td>Red</td>
<td>Therapy</td>
<td>Vincristine</td>
<td>injection</td>
<td></td>
<td>Vinca alkaloid</td>
<td>SPC</td>
<td></td>
<td>CG84 breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.4</td>
<td>Red</td>
<td>Therapy</td>
<td>Vinorelbine</td>
<td>injection</td>
<td>20mg, 30mg &amp; 80mg capsules</td>
<td>Vinca alkaloid</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Therapy</td>
<td>Aflibercept</td>
<td>Antineoplastic</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td>TA307 metastatic colorectal cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Therapy</td>
<td>Asparaginase</td>
<td>injection</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>------------------</td>
<td>--------------</td>
<td>----------------</td>
<td>-----------------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>------</td>
<td>------------------------------------------------------------------</td>
<td>----------------------</td>
<td>----------</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>renal cell carcinoma</td>
<td>Axitinib</td>
<td>tablet</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>TA333</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>8.1.5 Subject to a Managed Access Scheme</td>
<td>Venetoclax</td>
<td>10mg, 50mg &amp; 100mg tablet</td>
<td></td>
<td>Selective inhibitor of B-cell lymphoma</td>
<td>SPC</td>
<td>TA487</td>
<td>CLL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>8.1.5 Subject to Patient Access Scheme</td>
<td>Bortezomib</td>
<td>3.5mg injection</td>
<td></td>
<td>Proteasome inhibitor</td>
<td>SPC</td>
<td>TA319</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>8.1.5 Subject to Patient Access Scheme</td>
<td>Carboplatin</td>
<td>injection</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>TA464</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>8.1.5 Subject to Patient Access Scheme</td>
<td>Ceritinib</td>
<td>150mg capsule</td>
<td></td>
<td>ALK inhibitor</td>
<td>SPC</td>
<td>TA399</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>8.1.5 Subject to Patient Access Scheme</td>
<td>Cetuximab</td>
<td>injection</td>
<td></td>
<td>Monoclonal antibody</td>
<td>SPC</td>
<td>TA410</td>
<td>colorectal cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>head and neck cancer</td>
<td>TA426</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>recurrent or metastatic head &amp; neck cancer, not recommended</td>
<td>TA172</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>metastatic colorectal cancer, not supported</td>
<td>TA473</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>squamous cell cancer of head and neck</td>
<td>TA472</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>8.1.5 Subject to Managed Access Scheme</td>
<td>Atezolizumab</td>
<td>1200mg infusion</td>
<td></td>
<td>Monoclonal antibody</td>
<td>SPC</td>
<td>TA492</td>
<td>urothelial cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>non small cell lung cancer</td>
<td>Cisplatin</td>
<td>injection</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>TA381</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>cervical cancer</td>
<td></td>
<td></td>
<td></td>
<td>cervical cancer</td>
<td>TA383</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>gastric cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA308</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
<td>Comments</td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>-----------------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td>------</td>
<td>----------------------------------------------------------------</td>
<td>---------------------</td>
<td>----------</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Dacarbazine</td>
<td>injection</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Bosutinib</td>
<td>tablet</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td>TA601 CML, TA374 small cell lung cancer, TA425 CML, TA426 CML</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Dasatinib</td>
<td>tablet</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td>TA374 small cell lung cancer, TA425 CML, TA426 CML</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Docetaxel</td>
<td>injection</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td>TA101 prostate cancer, TA100 breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Erlotinib</td>
<td>tablet</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td>TA175 non small cell lung cancer, terminated appraisal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Gefitinib</td>
<td>250mg tablet</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>SPC</td>
<td></td>
<td>TA175 non small cell lung cancer, terminated appraisal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DPC: 14.8.12 12.6.12
MHRA: 9(10)May16
Subject to Patient Access Scheme

Also for head and neck cancer
Subject to Patient Access Scheme

Subject to Patient Access Scheme

MHRA: 9(10)May16
<table>
<thead>
<tr>
<th>BNF Ref.</th>
<th>RAG Status</th>
<th>Place in therapy</th>
<th>Drug Name</th>
<th>Form &amp; Strength</th>
<th>Brand (if applicable)</th>
<th>Main Indication / Action</th>
<th>Link to SPC</th>
<th>NICE</th>
<th>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</th>
<th>Special / ACBS / SLS</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Ibrutinib</td>
<td>140mg capsule</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>SPC</td>
<td></td>
<td>TA429 (CLL)</td>
<td>DPC: 3.7.07 &amp; 12.2.13</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA431 (Waldenstrom's macroglobulinaemia)</td>
<td>MHRA: 11(1)Aug17</td>
<td>Subject to Managed Access Scheme</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Idealisib</td>
<td>100mg &amp; 150mg tablet</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>SPC</td>
<td></td>
<td>TA359 (CLL)</td>
<td>MHRA: 10(2)Sep16</td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Imatinib</td>
<td>100mg &amp; 400mg tablet</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>SPC</td>
<td></td>
<td>TA486 (GIST)</td>
<td>DPC: 12.6.12 &amp; 12.10.10</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA489 (GIST, not recommended)</td>
<td>MHRA: 9(10)May16</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA490 (CML, not recommended)</td>
<td>MHRA: 9(10)May16</td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Palbociclib</td>
<td>75mg, 100mg &amp; 125mg</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>SPC</td>
<td></td>
<td>TA485 (breast cancer)</td>
<td>DPC: 3.7.07 &amp; 12.2.13</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Ribociclib</td>
<td>200mg tablet</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>SPC</td>
<td></td>
<td>TA486 (breast cancer)</td>
<td>DPC: 3.7.07 &amp; 12.2.13</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Brentuximab vedotin</td>
<td>50mg injection</td>
<td></td>
<td>Monoclonal antibody</td>
<td>SPC</td>
<td></td>
<td>TA494 (Hodgkins lymphoma) TA478 (lymphoma)</td>
<td>DPC: 12.8.14 &amp; 12.2.13</td>
<td>Subject to Managed Access Agreement</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Ipilimumab</td>
<td>5mg/ml concentrate</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td>TA368 melanoma TA319 melanoma TA440 advanced melanoma</td>
<td>DPC: 3.7.07</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>for infusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Ipinotecan</td>
<td>injection</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td>CG131 colorectal cancer</td>
<td>DPC: 12.6.12 &amp; 21.2.12</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Mitotane</td>
<td>tablet</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td></td>
<td>DPC: 12.6.12 &amp; 21.2.12</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Nilotinib</td>
<td>150mg &amp; 200mg capsule</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>SPC</td>
<td></td>
<td>TA426 (CML)</td>
<td>MHRA: 9(10)May16</td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
<td>Comments</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>-----------------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td>-----</td>
<td>----------------------------------------------------------</td>
<td>-------------------</td>
<td>----------</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Osimertinib</td>
<td>40mg &amp; 80mg tablet</td>
<td>Tyrosine kinase inhibitor</td>
<td>SPC</td>
<td>TA416</td>
<td>non-small cell lung cancer</td>
<td></td>
<td>Subject to Managed Access Agreement</td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Trametinib</td>
<td>500mcg &amp; 2mg capsule</td>
<td></td>
<td>SPC</td>
<td>TA396</td>
<td>metastatic melanoma</td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Oxaliplatin</td>
<td>Injection</td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>CG131</td>
<td>colorectal cancer</td>
<td>TA100</td>
<td>colon cancer</td>
<td>DPC: 15.6.10 - oesophagogastric cancer</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Cabazitaxel</td>
<td>Injection</td>
<td>Taxane</td>
<td>SPC</td>
<td>TA385</td>
<td>prostate cancer, not recommended</td>
<td>TA391</td>
<td>prostate cancer</td>
<td>DPC: 12.6.12</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Paclitaxel</td>
<td>Injection</td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>TA34</td>
<td>breast cancer</td>
<td>TA65</td>
<td>ovarian cancer</td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Paclitaxel albumin</td>
<td>Injection</td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>TA476</td>
<td>- pancreatic cancer</td>
<td></td>
<td>Formulated as albumin bound nanoparticles</td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Pazopanib</td>
<td>200mg &amp; 400mg tablet</td>
<td></td>
<td>SPC</td>
<td>TA315</td>
<td>renal cell carcinoma</td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Panobinostat</td>
<td>10mg, 15mg &amp; 20mg capsule</td>
<td></td>
<td>SPC</td>
<td>TA480</td>
<td>multiple myeloma</td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
<td>Comments</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>-----------------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>------</td>
<td>---------------------------------------------------------------</td>
<td>-----------------</td>
<td>----------</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Procarbazine</td>
<td>capsule</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>For CNS diffuse</td>
<td>Thiotepa</td>
<td>100mg powder</td>
<td>Thiotepa</td>
<td>Antineoplastic</td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B cell lymphoma</td>
<td></td>
<td>for infusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Sunitinib</td>
<td>capsule</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>TA362</td>
<td>metastatic renal cell carcinoma</td>
<td>DPC: 13.10.09 &amp; 17.4.09</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Temozolomide</td>
<td>capsule</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>TA283</td>
<td>glioma</td>
<td>MHRA: 7/6/Jan14</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Irinotecan</td>
<td>capsule</td>
<td></td>
<td>Topoisomerase I inhibitor</td>
<td>SPC</td>
<td>TA539</td>
<td>colorectal cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Topoisomerase I inhibitor</td>
<td>SPC</td>
<td>TA697</td>
<td>cervical cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Topotecan</td>
<td>injection</td>
<td></td>
<td>Topoisomerase I inhibitor</td>
<td>SPC</td>
<td>TA698</td>
<td>small cell lung cancer, oral - IV not recommended</td>
<td>OPC: 8.12.09</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>capsule</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Topoisomerase I inhibitor</td>
<td>SPC</td>
<td>TA699</td>
<td>ovarian cancer, not recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Trabectidin</td>
<td>250microgram &amp;</td>
<td></td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>TA695</td>
<td>soft tissue sarcoma</td>
<td>OPC: 14.6.11 &amp; 13.4.10</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1mg injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Topoisomerase I inhibitor</td>
<td>SPC</td>
<td>TA696</td>
<td>ovarian cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>-----------------</td>
<td>-----------</td>
<td>----------------</td>
<td>----------------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>------</td>
<td>-------------------------------------------------</td>
<td>----------------------</td>
<td>----------</td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Trastuzumab</td>
<td>Injection</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>TAC4</td>
<td></td>
<td>TA346, breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA347</td>
<td></td>
<td>TA347 - breast cancer, not recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA348</td>
<td></td>
<td>TA348 - breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA349</td>
<td></td>
<td>TA349 - breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DPC: 14.8.12 &amp; 14.12.10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Eribulin</td>
<td>880microgram injection</td>
<td></td>
<td>Antineoplastic</td>
<td>TAC443</td>
<td></td>
<td>TA421 - breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Tretinoin</td>
<td>capsule</td>
<td></td>
<td>Antineoplastic</td>
<td>TAC426</td>
<td></td>
<td>TAC426 - breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Idelalisib</td>
<td>tablet</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>TAC556</td>
<td></td>
<td>MHRA: 9(10)May16</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Nintedanib</td>
<td>100mg &amp; 150mg capsule</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>TAC441</td>
<td></td>
<td>TAC441 - non-small cell lung cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TAC441 - idiopathic pulmonary fibrosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Olaparib</td>
<td>50mg capsule</td>
<td></td>
<td>PARP enzyme inhibitor</td>
<td>TAC301</td>
<td></td>
<td>TAC301 - ovarian, fallopian tube and peritoneal cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Crizotinib</td>
<td>capsule</td>
<td></td>
<td>Kinase inhibitor</td>
<td>TAC446</td>
<td></td>
<td>TAC446 - non-small cell lung cancer</td>
<td>MHRA: 5(4)Nov15</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MHRA: 9(4)Nov15 of PARP enzyme inhibitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Everolimus</td>
<td>2.5mg, 5mg &amp; 10mg tablet</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>TAC423</td>
<td></td>
<td>TAC423 - breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TAC423 - renal cell carcinoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TAC423 - NETS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DPC: 14.6.11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td></td>
<td>Everolimus</td>
<td>2.5mg, 5mg &amp; 10mg tablet</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>TAC448</td>
<td></td>
<td>TAC448 - NETS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

December 2017
<table>
<thead>
<tr>
<th>BNF Ref.</th>
<th>RAG Status</th>
<th>Place in therapy</th>
<th>Drug Name</th>
<th>Form &amp; Strength</th>
<th>Main Indication / Action</th>
<th>Link to SPC</th>
<th>NICE</th>
<th>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</th>
<th>Special / ACBS / SLS</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Ruxolitinib</td>
<td>Antineoplastic</td>
<td>TA289 - myelofibrosis, not recommended</td>
<td>DPC: 13.8.13</td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Carfilzomib</td>
<td>10mg, 30mg &amp; 60mg injection</td>
<td>TA906 - splenomegaly &amp; myelofibrosis</td>
<td>DPC: 13.8.13</td>
<td>Subject to patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Ponatinib</td>
<td>15mg, 30mg &amp; 45mg tablet</td>
<td>TA463 - CML &amp; ALL</td>
<td>MHRA: 10(9)Apr17</td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Sorafenib</td>
<td>200mg tablet</td>
<td>TA474 - hepatocellular carcinoma</td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Cabozantinib</td>
<td>20mg, 40mg &amp; 60mg tablet</td>
<td>TA663 - renal cell carcinoma</td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Blinatumomab</td>
<td>3.5microgram injection</td>
<td>TA450 - ALL</td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Vemurafenib</td>
<td>Protein kinase inhibitor</td>
<td>TA289 - malignant melanoma</td>
<td>DPC: 12.2.13</td>
<td>MHRA: 15(1)Nov15</td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Regorafenib</td>
<td>Antineoplastic</td>
<td>TA394 colorectal cancer - not recommended</td>
<td>DPC: 13.8.13</td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.1</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Azathioprine</td>
<td>injection</td>
<td>Antiproliferative immunosuppressant</td>
<td>DPC: 13.8.13</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.1</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Mycophenolate mofetil</td>
<td>injection</td>
<td>Antiproliferative immunosuppressant</td>
<td>DPC: 13.8.13</td>
<td>MHRA: 8(4)Nov15</td>
<td>For allogenic BMT and PBSC transplant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.1</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Belimumab</td>
<td>infusion</td>
<td>Monoclonal antibody</td>
<td>TA312 SLE</td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.2</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Basiliximab</td>
<td>Immunosuppressant</td>
<td>TA481 renal transplant (adults)</td>
<td>DPC: 6.11.07 - for SLE (Classified as red)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.2</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Basiliximab</td>
<td>Immunosuppressant</td>
<td>TA481 renal transplant (adults)</td>
<td>DPC: 6.11.07 - for SLE (Classified as red)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.2</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Basiliximab</td>
<td>Immunosuppressant</td>
<td>TA481 renal transplant (adults)</td>
<td>DPC: 6.11.07 - for SLE (Classified as red)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.2</td>
<td>Red</td>
<td>Place in therapy</td>
<td>Basiliximab</td>
<td>Immunosuppressant</td>
<td>TA481 renal transplant (adults)</td>
<td>DPC: 6.11.07 - for SLE (Classified as red)</td>
<td>For allogenic BMT and PBSC transplant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>---------------------</td>
<td>------------------------</td>
<td>-------------</td>
<td>------</td>
<td>---------------------------------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>8.2.3</td>
<td>Red</td>
<td>Subject to patient Access Scheme</td>
<td>Obinutuzumab</td>
<td>injection</td>
<td>Anti-lymphocyte monoclonal antibody</td>
<td>TAA43 - CLL, TAA72 - lymphoma</td>
<td>Subject to patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.3</td>
<td>Red</td>
<td>Subject to patient Access Scheme</td>
<td>Ofatumumab</td>
<td>injection</td>
<td>Anti-lymphocyte monoclonal antibody</td>
<td>TAA44 - CLL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.3</td>
<td>Red</td>
<td>Subject to managed access scheme</td>
<td>Olaratumab</td>
<td>infusion</td>
<td>Monoclonal antibody</td>
<td>TAA65 - soft tissue</td>
<td>MHRA: 10(12)Jul11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.3</td>
<td>Red</td>
<td>Subject to Managed Access Agreement</td>
<td>Pembrolizumab</td>
<td>injection</td>
<td>Anti-lymphocyte monoclonal antibody</td>
<td>TAA67</td>
<td>MHRA Dec13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.3</td>
<td>Red</td>
<td>Specialist use only</td>
<td>Rituximab</td>
<td>injection</td>
<td>Anti-lymphocyte monoclonal antibody</td>
<td>TAA68 - vasculitis</td>
<td>TAA69 - non-Hodgkin lymphoma</td>
<td>TAA137 - follicular lymphoma</td>
<td>TAA74 - CLL</td>
<td>TAA89 - CLL</td>
</tr>
<tr>
<td>8.2.3</td>
<td>Red</td>
<td></td>
<td>Necitumumab</td>
<td>infusion</td>
<td>Monoclonal antibody</td>
<td>TAA412</td>
<td>non-small cell lung cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.3</td>
<td>Red</td>
<td>Subject to Patient Access Scheme</td>
<td>Pertuzumab</td>
<td>Monoclonal antibody</td>
<td>TAA424</td>
<td>breast cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.3</td>
<td>Red</td>
<td>Subject to Patient Access Scheme</td>
<td>Panitumumab</td>
<td>Monoclonal antibody</td>
<td>TAA429</td>
<td>colorectal cancer</td>
<td>TAA430</td>
<td>colorectal cancer, terminated appraisal</td>
<td>MHRA: 6(2)Sep12</td>
<td>MHRA: 7(2)Sep13</td>
</tr>
<tr>
<td>8.2.3</td>
<td>Red</td>
<td>Subject to Patient Access Scheme</td>
<td>Talimogene laherparepvec</td>
<td>injection</td>
<td>Immunotherapy agent</td>
<td>TAA430</td>
<td>metastatic melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.3</td>
<td>Red</td>
<td></td>
<td>Pegaspargase</td>
<td>injection</td>
<td>Immunomodulator</td>
<td>TAA408</td>
<td>ALL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>----------------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>------</td>
<td>-------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td>Specialised commissioning</td>
<td>Dimethyl fumarate</td>
<td>120mg &amp; 240mg capsules</td>
<td>Tecfidera</td>
<td>Relapsing remitting MS</td>
<td>SPC</td>
<td>TA320</td>
<td>DPC: 14.10.14 MHRA: 8(8)Mar15</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td>Specialised commissioning</td>
<td>Fingolimod</td>
<td>500 microgram capsules</td>
<td></td>
<td>Relapsing remitting MS</td>
<td>SPC</td>
<td>TA254</td>
<td>DPC: 12.6.12 MHRA: 5(10)May12</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td>Specialised commissioning</td>
<td>Daclizumab</td>
<td>150mg injection</td>
<td></td>
<td>Monoclonal antibody</td>
<td>SPC</td>
<td>TA441</td>
<td>MHRA: 9(9)Apr16</td>
<td>Subject to Patient Access Scheme</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td>Specialised commissioning</td>
<td>Glatiramer</td>
<td>20mg &amp; 40mg injection</td>
<td></td>
<td></td>
<td>SPC</td>
<td>TA32</td>
<td>MS, not recommended</td>
<td>Specialist use only for multiple sclerosis</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td>Specialised commissioning</td>
<td>Interferon alfa</td>
<td>injection</td>
<td></td>
<td></td>
<td>SPC</td>
<td>TA75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td>Specialised commissioning</td>
<td>Peginterferon alfa-2a</td>
<td>injection</td>
<td></td>
<td></td>
<td>SPC</td>
<td>TA75</td>
<td></td>
<td>Department of Health risk-sharing scheme for multiple sclerosis (UHS formulary)</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td>Specialised commissioning</td>
<td>Peginterferon alfa-2b</td>
<td>injection</td>
<td></td>
<td></td>
<td>SPC</td>
<td>TA75</td>
<td></td>
<td>For myeloproliferative disorders when refractory or patient intolerant to standard therapy</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td>Specialised commissioning</td>
<td>Peginterferon beta-1A</td>
<td>injection</td>
<td></td>
<td></td>
<td>SPC</td>
<td>TA32</td>
<td></td>
<td>For multiple sclerosis</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td></td>
<td>Interferon beta</td>
<td>injection</td>
<td></td>
<td></td>
<td>SPC</td>
<td>TA32</td>
<td>MS, not recommended</td>
<td>For multiple sclerosis</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td></td>
<td>BCG</td>
<td>Bladder instillation</td>
<td></td>
<td></td>
<td>SPC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>------------------</td>
<td>-----------</td>
<td>-----------------</td>
<td>-----------------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>------</td>
<td>-------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td></td>
<td>Lenalidomide</td>
<td>5mg, 10mg, 15mg &amp; 25mg capsule</td>
<td></td>
<td>Immunomodulator</td>
<td>SPC</td>
<td>TA171</td>
<td>multiple myeloma</td>
<td>DPC: 9.2.10 - Priorities Committee, multiple myeloma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA22</td>
<td>myeloblastic syndromes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA35</td>
<td>osteosarcoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA22</td>
<td>multiple myeloma</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td></td>
<td>Thalidomide</td>
<td>50mg capsule</td>
<td></td>
<td>Immunomodulator</td>
<td>SPC</td>
<td>TA22</td>
<td>multiple myeloma</td>
<td>DPC: 9.8.11 &amp; 16.5.06</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA122</td>
<td>relapsing remitting MS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA122</td>
<td>relapsing remitting MS</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td></td>
<td>Nativizumab</td>
<td>300mg infusion</td>
<td></td>
<td>Immunomodulator</td>
<td>SPC</td>
<td>TA84</td>
<td>advanced melanoma</td>
<td>MHRA: 10/12Jul17</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA84</td>
<td>advanced melanoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA141</td>
<td>renal cell carcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA84</td>
<td>renal cell carcinoma</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td></td>
<td>Tariffumide</td>
<td>solution for infusion</td>
<td>Human immunoglobin monoclonal antibody</td>
<td>Immunomodulator</td>
<td>SPC</td>
<td>TA601</td>
<td>relapsing remitting MS</td>
<td>MHRA: 9/10May16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA601</td>
<td>relapsing remitting MS</td>
</tr>
<tr>
<td>8.2.4</td>
<td>Red</td>
<td></td>
<td>Pomalidomide</td>
<td>1mg, 2mg, 3mg &amp; 4mg capsule</td>
<td></td>
<td>Immunomodulator</td>
<td>SPC</td>
<td>TA22</td>
<td>multiple myeloma , not recommended</td>
<td>MHRA: 8/10May15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA22</td>
<td>multiple myeloma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA256</td>
<td>prostate cancer</td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Red</td>
<td></td>
<td>Abiraterone</td>
<td>250mg tablet</td>
<td></td>
<td>Anti-androgen</td>
<td>SPC</td>
<td>TA256</td>
<td>prostate cancer</td>
<td>DPC: 14.8.12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA256</td>
<td>prostate cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TA256</td>
<td>prostate cancer</td>
</tr>
<tr>
<td>BNF Ref.</td>
<td>RAG Status</td>
<td>Place in therapy</td>
<td>Drug Name</td>
<td>Form &amp; Strength</td>
<td>Brand (if applicable)</td>
<td>Main Indication / Action</td>
<td>Link to SPC</td>
<td>NICE</td>
<td>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</td>
<td>Special / ACBS / SLS</td>
</tr>
<tr>
<td>----------</td>
<td>------------</td>
<td>-------------------</td>
<td>-----------</td>
<td>----------------</td>
<td>----------------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td>------</td>
<td>---------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Red</td>
<td>Metastatic prostate cancer</td>
<td>TA316 prostate cancer</td>
<td>OPC</td>
<td>DPC: 12.8.14</td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Red</td>
<td>Metastatic prostate cancer</td>
<td>TA377 prostate cancer</td>
<td>OPC</td>
<td>DPC: 12.8.14</td>
<td>Subject to Patient Access Scheme</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.2</td>
<td>Red</td>
<td>Metastatic prostate cancer</td>
<td>TA412 prostate cancer</td>
<td>OPC</td>
<td>DPC: 13.8.13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Black</td>
<td>Antimetabolites</td>
<td>TA270 AML, terminated appraisal</td>
<td>DPC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.3</td>
<td>Black</td>
<td>Antimetabolites</td>
<td>TA93 colorectal cancer, not recommended</td>
<td>DPC: 12.4.11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.4</td>
<td>Black</td>
<td>Vinca alkaloid</td>
<td>TA272 carcinoma of urothelial tract, not recommended</td>
<td>DPC: 12.2.13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Black</td>
<td>Antineoplastic</td>
<td>TA307 colorectal cancer, not recommended</td>
<td>DPC: 22.4.14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Black</td>
<td>Antineoplastic</td>
<td>TA418 colorectal cancer, not recommended</td>
<td>DPC: 21.2.12, 12.4.11 &amp; 13.10.09</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NOT SUPPORTED BY DPC

<table>
<thead>
<tr>
<th>BNF Ref.</th>
<th>RAG Status</th>
<th>Place in therapy</th>
<th>Drug Name</th>
<th>Form &amp; Strength</th>
<th>Brand (if applicable)</th>
<th>Main Indication / Action</th>
<th>Link to SPC</th>
<th>NICE</th>
<th>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</th>
<th>Special / ACBS / SLS</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1.5</td>
<td>Black</td>
<td>Antineoplastic</td>
<td>TA418 colorectal cancer, not recommended</td>
<td>DPC: 21.2.12, 12.4.11 &amp; 13.10.09</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

 Spells December 2017

Formulary Chap8 Update Dec 2018
<table>
<thead>
<tr>
<th>BNF Ref.</th>
<th>RAG Status</th>
<th>Place in therapy</th>
<th>Drug Name</th>
<th>Form &amp; Strength</th>
<th>Brand (if applicable)</th>
<th>Main Indication / Action</th>
<th>Link to SPC</th>
<th>NICE</th>
<th>Special / ACBS / SLS</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>TA178</td>
<td>Black</td>
<td></td>
<td>Sorafenib</td>
<td>Antineoplastic</td>
<td>SPB</td>
<td>TA178 - renal cell carcinoma, not recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA256</td>
<td>Black</td>
<td></td>
<td>Abraxane</td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>TA256 - metastatic adenoma, not recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA302</td>
<td>Black</td>
<td></td>
<td></td>
<td></td>
<td>PA</td>
<td>TA302 - NSCL cancer, terminated appraisal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA362</td>
<td>Black</td>
<td></td>
<td></td>
<td></td>
<td>PA</td>
<td>TA362 - NSCL cancer, terminated appraisal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA378</td>
<td>Black</td>
<td></td>
<td>Bevacizumab</td>
<td>Antineoplastic</td>
<td>SPC</td>
<td>TA378 - not supported for gastrointestinal cancers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA178</td>
<td>Black</td>
<td></td>
<td></td>
<td></td>
<td>PA</td>
<td>TA178 - renal cell carcinoma, not recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA296</td>
<td>Black</td>
<td></td>
<td></td>
<td></td>
<td>PA</td>
<td>TA296 - low priority, Priorities Committee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA356</td>
<td>Black</td>
<td></td>
<td></td>
<td></td>
<td>PA</td>
<td>TA356 - metastatic adenoma, not recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA353</td>
<td>Black</td>
<td></td>
<td></td>
<td></td>
<td>PA</td>
<td>TA353 - terminated appraisal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA284</td>
<td>Black</td>
<td></td>
<td></td>
<td></td>
<td>PA</td>
<td>TA284 - ovarian cancer, not recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA285</td>
<td>Black</td>
<td></td>
<td></td>
<td></td>
<td>PA</td>
<td>TA285 - ovarian cancer, not recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA263</td>
<td>Black</td>
<td></td>
<td></td>
<td></td>
<td>PA</td>
<td>TA263 - breast cancer, not recommended</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8.1.5 Black Bexarotene Antineoplastic SPC

8.1.5 Black Crizotinib capsule Tyrosine kinase inhibitor SPC

8.1.5 Black Cobimetinib 20mg tablet Protein kinase inhibitor SPC

8.1.5 Black Idelalisib Protein kinase inhibitor SPC

8.1.5 Black Lapatinib Protein kinase inhibitor SPC

8.1.5 Black Ramucirumab solution for infusion Inhibits activation of VEGF Receptor 2 SPC

8.1.5 Black Ruxolitinib Protein kinase inhibitor SPC

8.1.5 Black Nanoparticle albumin bound paclitaxel Abraxane Antineoplastic SPC

DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA

DPC: 14.12.10 - Priorities Committee, cutaneous T-cell lymphoma, not supported

DPC: 12.4.11 & 13.10.09

DPC: 15.6.10 - low priority, Priorities Committee

DPC: 15.6.10 - low priority, Priorities Committee

Formulary Chap8 Update Dec 2018
<table>
<thead>
<tr>
<th>BNF Ref.</th>
<th>RAG Status</th>
<th>Place in therapy</th>
<th>Drug Name</th>
<th>Form &amp; Strength</th>
<th>Brand (if applicable)</th>
<th>Main Indication / Action</th>
<th>Link to SPC</th>
<th>NICE</th>
<th>DPC, Local guidance (LG), Antibiotic (AB) guidelines, MHRA/NPSA</th>
<th>Special / ACBS / SLS</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1.5</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Sorafenib</td>
<td></td>
<td></td>
<td></td>
<td>TA189</td>
<td></td>
<td>hepaticcellular carcinoma, not recommended</td>
<td>TA189</td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Ramucirumab</td>
<td>infusion</td>
<td></td>
<td>Antibody to VEGF receptor 2</td>
<td>TA403</td>
<td></td>
<td>non-small cell lung cancer, not recommended</td>
<td>TA403</td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Alectinib</td>
<td>150mg capsule</td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>TA438</td>
<td></td>
<td>non-small cell lung cancer, terminated appraisal</td>
<td>TA438</td>
<td></td>
</tr>
<tr>
<td>8.1.5</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Temsirolimus</td>
<td></td>
<td></td>
<td>Protein kinase inhibitor</td>
<td>TA176</td>
<td></td>
<td>renal cell carcinoma, not recommended</td>
<td>TA176</td>
<td></td>
</tr>
<tr>
<td>8.2.1</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Mycophenolate sodium</td>
<td></td>
<td></td>
<td>Antiproliferative immunosuppressant</td>
<td>TA90</td>
<td></td>
<td>renal transplant (children)</td>
<td>TA90</td>
<td></td>
</tr>
<tr>
<td>8.2.3</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Elotuzumab</td>
<td>infusion</td>
<td></td>
<td>Monoclonal antibody</td>
<td>TA434</td>
<td></td>
<td>multiple myeloma, terminated appraisal</td>
<td>TA434</td>
<td></td>
</tr>
<tr>
<td>8.2.3</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Ofatumumab</td>
<td></td>
<td></td>
<td>Anti/lymphocyte monoclonal antibody</td>
<td>TA202</td>
<td></td>
<td>CLL, not recommended</td>
<td>TA202</td>
<td></td>
</tr>
<tr>
<td>8.2.4</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Canakinumab</td>
<td></td>
<td></td>
<td></td>
<td>TA281</td>
<td></td>
<td>gouty arthritis, terminated appraisal</td>
<td>TA281</td>
<td></td>
</tr>
<tr>
<td>8.2.4</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Pomalidomide</td>
<td></td>
<td></td>
<td></td>
<td>TA338</td>
<td></td>
<td>multiple myeloma, not recommended</td>
<td>TA338</td>
<td></td>
</tr>
<tr>
<td>8.3.4.1</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Fulvestrant</td>
<td>250mg prefilled syringe</td>
<td>Hormone antagonist in breast cancer</td>
<td>TA290</td>
<td></td>
<td>breast cancer, not recommended</td>
<td>TA290</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3.4.1</td>
<td>Black</td>
<td>BNF Ref.</td>
<td>Sipuleucel-T</td>
<td></td>
<td></td>
<td>Autologous cellular immunotherapy</td>
<td>TA332</td>
<td></td>
<td>prostate cancer, not recommended</td>
<td>TA332</td>
<td></td>
</tr>
</tbody>
</table>

DPC: 14.12.10 & 13.10.09

DPC: 21.2.12

MHRA: 9(10)May16